Abstract
Background. In order to determine whether recombinant human erythropoietin (rHuEPO) may play a role in treating anemia in idiopathic myelofibrosis (IMF), a pilot study using high doses of rHuEPO was conducted on patients with IMF. Methods and results. From September, 1990 to December, 1992, 7 patients (6 males and 1 female, median age 68 years) affected by IMF entered the trial. RHuEPO was administered subcutaneously 5 days a week at a dosage of 160 U/kg daily for three mouths. Out of 7 patients, 4 obtained a response. These responders received additional maintenance treatment with rHuEPO until relapse. Response duration was 6, 7, 10+, and 16 months, respectively. Treatment was well-tolerated. Conclusions. Our data suggest that rHuEPO may play a role in the treatment of anemia in some IMF patients.
| Original language | English |
|---|---|
| Pages (from-to) | 371-373 |
| Number of pages | 3 |
| Journal | Haematologica |
| Volume | 78 |
| Issue number | 6 |
| Publication status | Published - 1993 |
Keywords
- erythropoietin
- idiopathic myelofibrosis
ASJC Scopus subject areas
- Hematology